为极重型再生障碍性贫血患儿点亮生命之光

Core Viewpoint - The successful implementation of haploidentical stem cell transplantation for a child with severe aplastic anemia at Tianjin Children's Hospital marks a significant breakthrough in the treatment capabilities for critical blood disorders in children [1][2]. Group 1: Medical Achievement - The child underwent haploidentical stem cell transplantation under the guidance of experts from Peking University People's Hospital, with the new hematopoietic system showing orderly reconstruction post-transplant [1]. - Severe aplastic anemia is characterized by rapid onset and progression, leading to near-total failure of the child's hematopoietic function, making the condition life-threatening [1]. Group 2: Technological Advancement - The haploidentical transplantation technique used is recognized internationally as a high-difficulty frontier technology, overcoming the traditional requirement for complete HLA compatibility between donor and recipient [1]. - This advancement allows relatives, such as parents, to serve as potential donors, addressing the global challenge of donor shortages [1]. Group 3: Implementation of the "Beijing Plan" - The "Beijing Plan," developed by Peking University Blood Disease Research Institute, accounts for over 95% of haploidentical transplants in China and was deemed the most suitable option for the child due to severely low bone marrow function [2]. - The collaboration between Tianjin Children's Hospital and leading experts, including Professor Cheng Yifei, ensured a personalized and precise approach to the transplantation process, enhancing the likelihood of success [2]. Group 4: Future Implications - The successful application of this technology is seen as a critical step towards not only benefiting more children with leukemia and aplastic anemia but also expanding treatment options for congenital immunodeficiencies and rare genetic metabolic diseases [2].